QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:ATRC

AtriCure - ATRC Stock Forecast, Price & News

$44.09
-3.11 (-6.59%)
(As of 02/6/2023 04:30 PM ET)
Add
Compare
Today's Range
$44.06
$47.41
50-Day Range
$41.37
$47.22
52-Week Range
$32.51
$72.31
Volume
296,914 shs
Average Volume
283,292 shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.67

AtriCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.9% Upside
$60.67 Price Target
Short Interest
Healthy
2.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of AtriCure in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.10) to ($0.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

415th out of 1,027 stocks

Surgical & Medical Instruments Industry

43rd out of 105 stocks

ATRC stock logo

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Stock News Headlines

StockNews.com Upgrades AtriCure (NASDAQ:ATRC) to Hold
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Estimating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
AtriCure Reports Third Quarter 2022 Financial Results
AtriCure to Announce Third Quarter 2022 Financial Results
Oversold Conditions For AtriCure (ATRC) - Nasdaq
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Company Calendar

Last Earnings
11/03/2021
Today
2/06/2023
Next Earnings (Confirmed)
2/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
875
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$60.67
High Stock Price Forecast
$71.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+37.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$50.20 million
Pretax Margin
-17.69%

Debt

Sales & Book Value

Annual Sales
$274.33 million
Cash Flow
$0.89 per share
Book Value
$10.53 per share

Miscellaneous

Free Float
45,206,000
Market Cap
$2.05 billion
Optionable
Optionable
Beta
1.26

Social Links


Key Executives

  • Michael H. Carrel
    President, Chief Executive Officer & Director
  • Douglas J. SeithDouglas J. Seith
    Chief Operating Officer
  • Angela L. WirickAngela L. Wirick
    Chief Financial Officer
  • Vinayak DoraiswamyVinayak Doraiswamy
    Chief Scientific Officer
  • Salvatore PriviteraSalvatore Privitera
    Chief Technical Officer













ATRC Stock - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price forecast for 2023?

4 equities research analysts have issued twelve-month target prices for AtriCure's shares. Their ATRC share price forecasts range from $50.00 to $71.00. On average, they expect the company's share price to reach $60.67 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2023?

AtriCure's stock was trading at $44.38 at the beginning of the year. Since then, ATRC stock has increased by 6.4% and is now trading at $47.20.
View the best growth stocks for 2023 here
.

Are investors shorting AtriCure?

AtriCure saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 1,290,000 shares, a decline of 10.4% from the December 31st total of 1,440,000 shares. Based on an average trading volume of 269,100 shares, the short-interest ratio is presently 4.8 days. Currently, 2.8% of the shares of the stock are sold short.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our ATRC earnings forecast
.

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Tuesday, February 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings data on Wednesday, November, 3rd. The medical device company reported $2.11 EPS for the quarter, beating the consensus estimate of ($0.28) by $2.39. The medical device company had revenue of $70.46 million for the quarter, compared to analyst estimates of $68.95 million. AtriCure had a negative trailing twelve-month return on equity of 12.09% and a negative net margin of 17.76%. During the same quarter in the prior year, the firm posted ($0.11) EPS.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of -$1.12--$1.10 for the period, compared to the consensus estimate of -$1.10. The company issued revenue guidance of $330.40 million-$330.40 million, compared to the consensus revenue estimate of $330.06 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different institutional and retail investors. Top institutional investors include Emerald Advisers LLC (1.11%), Emerald Mutual Fund Advisers Trust (0.87%), New York State Common Retirement Fund (0.52%), Peregrine Capital Management LLC (0.34%), Congress Asset Management Co. MA (0.19%) and Oak Ridge Investments LLC (0.13%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $47.20.

How much money does AtriCure make?

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.20 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does AtriCure have?

The company employs 875 workers across the globe.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 2/6/2023 by MarketBeat.com Staff